This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Sector Settles on Trading Higher After Choppy Morning

The biotech sector was having some trouble settling on a direction earlier in today's trading session, but lately the measures that track the group were firmly in positive territory.

The American Stock Exchange Biotech Index was recently up 3%. The Dow Jones Biotech Index were gaining 1.2%, and the Biotech HOLDRs was also rising 1.2%. The latter two were down earlier in the session.

Applied Biosystems (ABI), a part of Applera, posted earnings of 22 cents a share this morning, a penny below the Thomson Financial/First Call estimate, and 4 cents below last year's same-quarter comparison. Revenue rose 3.5% in the quarter, and the company said it expects a slowdown in capital purchases and currency effects to "restrain revenue growth for the next few quarters" traders seemed keen on the stock today. Shares of Applied Biosystems were climbing 7.5% to $27.42.

Celera Genomics (CRA), the other company operating under the Applera umbrella, reported a wider-than-expected loss of 56 cents a share this morning. Analysts expected a loss of 54 cents a share. Celera, which is moving a large amount of its expenditures to drug discovery and research and away from online information, recently rose 7% to $31.20.

Amgen (AMGN - Get Report), which is posting earnings after the bell, fell 3.7% to $57 today. Chiron (CHIR), which beat earnings estimates by a penny yesterday, also slipped, falling 0.2% to $42. Genome Therapeutics (GENE) was climbing 0.7% to $12.45, and Genzyme General (GENZ) rose 6.3% to $55.42. Shares of Biogen (BGEN) were slipping 0.2% to $52.84.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AMGN $158.26 -1.40%
AAPL $93.75 -1.10%
FB $117.53 0.69%
GOOG $693.00 0.29%
TSLA $240.75 -2.80%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,066.17 -9.64 -0.46%
NASDAQ 4,776.3210 -28.97 -0.60%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs